Table 3.
Poor | Intermediate | Recommended | |
---|---|---|---|
No family history of premature CHDe (n=9006) | |||
N events | 618 | 377 | 550 |
N total | 3065 | 2329 | 3612 |
Incidence ratea | 9.8 (9.1, 10.6) | 7.7 (6.9, 8.5) | 7.2 (6.6, 7.8) |
Model 1b | Ref | 0.82 (0.72, 0.93) | 0.70 (0.62, 0.79) |
Model 2c | Ref | 0.91 (0.80, 1.04) | 0.83 (0.73, 0.94) |
Model 3d | Ref | 0.89 (0.78, 1.02) | 0.83 (0.73, 0.94) |
Family history of premature CHDe (n=990) | |||
N events | 67 | 46 | 65 |
N total | 333 | 253 | 404 |
Incidence ratea | 10.1 (7.9, 12.8) | 8.7 (6.5, 11.6) | 7.6 (6.0, 9.7) |
Model 1b | Ref | 0.92 (0.63, 1.35) | 0.76 (0.54, 1.09) |
Model 2c | Ref | 1.02 (0.69, 1.51) | 0.92 (0.63, 1.33) |
Model 3d | Ref | 0.98 (0.66, 1.46) | 0.80 (0.55, 1.17) |
AHA indicates American Heart Association; ARIC, Atherosclerosis Risk in Communities; ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; CHD, coronary heart disease; FHx, family history; GFR, glomerular filtration rate; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; PA, physical activity.
Incidence rate is per 1000 person‐years.
Model 1: Age, sex, race/center.
Model 2: Model 1+education, BMI, smoking status, and alcohol intake.
Model 3: Model 2+additional potential mediating variables (of the association between PA and ASCVD risk)−systolic blood pressure, antihypertensive medication use, diabetes, LDL cholesterol, HDL cholesterol, triglycerides, use of lipid‐lowering medications, and estimated GFR.
P‐interaction for FHx (Model 2)=0.680.